EPO-5 is a synthetic short peptide analog of erythropoietin used in pre-clinical research to investigate EPO receptor (EPOR) interactions, selective receptor activation without hematopoietic effects, and downstream signaling in cellular research models. This research-grade peptide is produced under stringent GMP-compliant conditions and provided as a lyophilized powder to ensure superior purity, stability, and reliability in experimental applications.
Engineered solely for preclinical investigations, each batch of EPO-5 undergoes a comprehensive quality assessment and includes complete documentation, including a Certificate of Analysis (COA), purity data, and structural verification.
Scientific Overview
EPO-5 functions as a mimetic peptide that engages EPO receptor pathways in laboratory research settings. Preclinical literature has examined EPO-5 and related analogs in the following in vitro and in vivo research contexts:
- Selective activation of EPO receptor signaling without broad hematopoietic stimulation in cellular assay models
- Modulation of oxidative stress response pathways in cell-based experimental systems
- Investigation of non-hematopoietic receptor signaling in laboratory paradigms
- Support for studies on receptor dimerization and downstream intracellular cascades
- Examination of inflammatory and apoptotic pathway modulation in in vitro cellular systems
Why Researchers Choose Our EPO-5
For laboratories requiring dependable EPO-5 research peptide, our manufacturing process prioritizes reproducibility and scientific precision. Every batch is confirmed for:
- Purity ≥99% by HPLC
- Structural identity via mass spectrometry
- Third-party Certificate of Analysis (COA) available per lot
For Research Use Only. Not for human use. Statements regarding EPO-5 have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Explore our testing protocols in About Peptides > Rigorous Testing.
Research-Referenced Functional Attributes
(Based on existing preclinical and published literature data — not intended as claims of therapeutic use. For laboratory and research purposes only.)
- Mimetic binding to the EPO receptor leading to selective intracellular signaling in cellular models, as documented in related mimetic discovery literature (pmc.ncbi.nlm.nih.gov)
- Non-hematopoietic receptor pathway activation studied in preclinical in vitro models (pmc.ncbi.nlm.nih.gov)
- Investigation of non-hematopoietic signaling analogs in cellular research paradigms (pmc.ncbi.nlm.nih.gov)
- Support for investigations into receptor-specific agonism and downstream intracellular cascades in laboratory settings
- Examination of short peptide interactions with EPO receptor interfaces in vitro
- Study of cellular response mechanisms in oxidative or hypoxic in vitro research systems
